Arbutus Biopharma Corporation Forecast, price target & analysts
Arbutus Biopharma Corporation Target price 2025 - Analyst rating & recommendation
Arbutus Biopharma Corporation Classifications & Recommendation:
Arbutus Biopharma Corporation Price Target
| Target Price | $5.10 |
| Price | $3.13 |
| Potential |
62.94%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target Arbutus Biopharma Corporation 2026 .
The average Arbutus Biopharma Corporation target price is $5.10.
This is
62.94%
register free of charge
$7.35
134.82%
register free of charge
$4.04
29.07%
register free of charge
|
|
| A rating was issued by 10 analysts: 8 Analysts recommend Arbutus Biopharma Corporation to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Arbutus Biopharma Corporation stock has an average upside potential 2026 of
62.94%
register free of charge
|
Sales and Margin forecast 2025, 2026 & 2027
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 6.17 | 6.38 |
| 65.99% | 3.37% | |
| Net Margin | -1,133.23% | -819.15% |
| 182.18% | 27.72% |
7 Analysts have issued a sales forecast Arbutus Biopharma Corporation 2025 . The average Arbutus Biopharma Corporation sales estimate is
This results in the following potential growth metrics:
7 Arbutus Biopharma Corporation Analysts have issued a net profit forecast 2025. The average Arbutus Biopharma Corporation net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.38 | -0.27 |
| 13.64% | 28.95% | |
| P/E | negative | |
| EV/Sales | 76.32 |
7 Analysts have issued a Arbutus Biopharma Corporation forecast for earnings per share. The average Arbutus Biopharma Corporation EPS is
This results in the following potential growth metrics and future valuations:
Arbutus Biopharma Corporation...
Current Arbutus Biopharma Corporation Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Chardan Capital |
Locked
➜
Locked
|
Locked | Mar 28 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 21 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Nov 20 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 18 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 07 2024 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Nov 06 2024 |
| Jefferies |
Locked
➜
Locked
|
Locked | Sep 05 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Mar 28 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 21 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Nov 20 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 18 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 07 2024 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Nov 06 2024 |
|
Locked
Jefferies:
Locked
➜
Locked
|
Sep 05 2024 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
